RPGLIFE
RPG Life Sciences Limited (RPGLIFE) Stock Analysis
RPG Life Sciences Limited develops and markets pharmaceuticals in cardiology, diabetes, and primary care segments. It manufactures formulations for India and exports. The company is part of the RPG group healthcare business. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹2,863.50
-1.14% 1W | +18.40% 52W
Market Cap
4.7k CR
P/E Ratio
39.6
52W High
₹3127.8
52W Low
₹1733
Div. Yield
0.88%
Beta
-0.1
50 DMA
₹2751.9
200 DMA
₹2336
Profit Margin
16.3%
Inst. Own.
5.6%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating Profit | 49 | 25 | 35 | 39 | 40 | 33 | 43 |
| OPM % | 28% | 18% | 21% | 21% | 22% | 19% | 22% |
| Other Income | 3 | 115 | 5 | 16 | -5 | 14 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26% | 13% | 26% | 25% | 24% | 26% | 26% |
| Net Profit | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS in Rs | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 | 18.60 |
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 653 | 708 | 734 |
| Expenses | 493 | 560 | 579 |
| Operating Profit | 161 | 148 | 155 |
| OPM % | 25% | 21% | 21% |
| Other Income | 95 | 29 | 29 |
| Interest | 2 | 2 | 1 |
| Depreciation | 21 | 21 | 22 |
| Profit before tax | 233 | 154 | 160 |
| Tax % | 21% | 25% | |
| Net Profit | 183 | 115 | 120 |
| EPS in Rs | 110.79 | 69.64 | 72.34 |
| Dividend Payout % | 22% | 34% |
Shareholding Pattern
Promoters72.95%
FIIs1.11%
DIIs6.70%
Public19.23%
Promoters72.95%
FIIs1.00%
DIIs7.04%
Public19.01%
Promoters72.95%
FIIs0.87%
DIIs7.45%
Public18.72%
Promoters72.95%
FIIs0.95%
DIIs8.68%
Public17.42%
Promoters72.95%
FIIs0.87%
DIIs9.93%
Public16.24%
Promoters72.82%
FIIs0.38%
DIIs0.11%
Public26.70%
Promoters72.82%
FIIs0.90%
DIIs2.16%
Public24.12%
Promoters72.95%
FIIs1.46%
DIIs6.14%
Public19.46%
Promoters72.95%
FIIs0.87%
DIIs7.45%
Public18.72%
Promoters72.95%
FIIs0.87%
DIIs9.93%
Public16.24%
RPGLIFE
Holdings Analysis
Key strengths & risk signals
83
Overall
74
Fundamental
92
Technical
Risks (1)
NEGLIGIBLE DIVIDEND! 0.88% yield - little to no income.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (2751.9) is above 200-day average (2336.0) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 48,904 vs down days: 22,346. Ratio: 2.19x
Fundamental & Technical Analysis
83Overall
74Fundamental
92Technical
Fundamental Breakdown
Growth Quality
24/30
Revenue CAGR: 11.3% (GOOD, 11/15). Profit CAGR: 19.4% (VERY GOOD, 13/15).
Profit Margin
6/10
GOOD EFFICIENCY! 16.3% profit margin - above average profitability.
PEG Valuation
7/10
OVERVALUED! PEG of 2.04 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.88% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.24 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 26.58% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2751.9) is above 200-day average (2336.0) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (2863.5) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
6/10
POSITIVE YEAR! Stock gained 18.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 48,904 vs down days: 22,346. Ratio: 2.19x
RSI
3/5
NEUTRAL! RSI at 51.3 - balanced momentum.
52W Range
5/5
STRONG! Trading at 81.1% of 52W range - near yearly highs.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -1.1% (1 week), 6.1% (1 month), 4.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of -0.10 - stable stock, less market risk.
RPGLIFE
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-08 | Concall PDF | |
| Q1FY262025-10-24 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPGLIFE | ₹2,863.50 | 39.6 | 16.3% | 11.3% | 19.4% | +18.4% | 83 | BREAKOUT | +17.1% | +3.0% | +15.9% | +10.6% |
| GUJTHEM | ₹371.80 | 83.2 | 28.0% | 3.8% | -7.0% | -11.7% | 57 | BREAKDOWN | +22.0% | +1.8% | +22.0% | -0.9% |
| NOVARTIND | ₹2,013.20 | 50.8 | 26.4% | -1.4% | -3.4% | +204.8% | 65 | CONSOLIDATING DOWN | +16.7% | +27.8% | +18.5% | +14.6% |
| ORCHPHARMA | ₹979.40 | 608.3 | 3.5% | 22.3% | -40.1% | +35.1% | 67 | APPROACHING RESISTANCE | -156.1% | -86.6% | +15.6% | +28.0% |
| GUFICBIO | ₹418.60 | 57.2 | 7.5% | 6.1% | -6.9% | +11.3% | 63 | BOUNCE FROM SUPPORT | +70.2% | +1.8% | +16.6% | +3.6% |
| AARTIDRUGS | ₹413.60 | 19.8 | 7.1% | -2.3% | 5.4% | -19.3% | 55 | BOUNCE FROM SUPPORT | -6.9% | -9.1% | +19.0% | -2.4% |
| UNICHEMLAB | ₹529.90 | 12.3 | 13.2% | 18.4% | – | +11.0% | 66 | CONSOLIDATING UP | -495.2% | +280.7% | +20.1% | +10.0% |
| SOLARA | ₹662.60 | – | -0.1% | -1.2% | – | +8.3% | 52 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
Data from TradeAlone · Updated daily
